FUSN Fusion Pharmaceuticals Inc. Stock Quote

FUSN [NASD]

Index	-	P/E	-	EPS (ttm)	-1.75	Insider Own	0.70%	Shs Outstand	43.36M	Perf Week	-5.94%
Market Cap	83.55M	Forward P/E	-	EPS next Y	-2.10	Insider Trans	-37.37%	Shs Float	34.24M	Perf Month	-13.81%
Income	-75.60M	PEG	-	EPS next Q	-0.52	Inst Own	65.50%	Short Float	0.07%	Perf Quarter	-46.07%
Sales	2.10M	P/S	39.79	EPS this Y	47.40%	Inst Trans	-0.01%	Short Ratio	0.71	Perf Half Y	-75.21%
Book/sh	4.59	P/B	0.45	EPS next Y	-9.40%	ROA	-30.70%	Target Price	16.25	Perf Year	-74.79%
Cash/sh	4.89	P/C	0.42	EPS next 5Y	-	ROE	-33.90%	52W Range	1.99 - 9.50	Perf YTD	-50.60%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-35.40%	52W High	-78.32%	Beta	-
Dividend %	-	Quick Ratio	17.90	Sales past 5Y	-	Gross Margin	-	52W Low	3.52%	ATR	0.14
Employees	86	Current Ratio	17.90	Sales Q/Q	20.00%	Oper. Margin	-	RSI (14)	29.77	Volatility	7.11% 6.09%
Optionable	Yes	Debt/Eq	0.05	EPS Q/Q	30.40%	Profit Margin	-	Rel Volume	3.20	Prev Close	2.14
Shortable	Yes	LT Debt/Eq	0.05	Earnings	Aug 09 BMO	Payout	-	Avg Volume	36.23K	Price	2.06
Recom	1.50	SMA20	-10.25%	SMA50	-24.12%	SMA200	-61.64%	Volume	115,827	Change	-3.74%

Jul-06-22

Initiated

William Blair

Outperform

Oct-19-21

Resumed

Morgan Stanley

Overweight

$19

Aug-26-21

Initiated

B. Riley Securities

Buy

$17

Jul-21-20

Initiated

Wedbush

Outperform

$25

Jul-21-20

Initiated

Jefferies

Buy

$25

Jul-21-20

Initiated

Cowen

Outperform

Aug-13-22 08:09AM	Insider Buying: The Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Independent Director Just Bought 370% More Shares Simply Wall St.
Aug-12-22 09:35AM	After Plunging 14.9% in 4 Weeks, Here's Why the Trend Might Reverse for Fusion Pharmaceuticals Inc. (FUSN) Zacks +7.00%
Aug-09-22 08:25AM	Fusion Pharmaceuticals Inc. (FUSN) Reports Q2 Loss, Tops Revenue Estimates Zacks -6.85%
07:00AM	Fusion Pharmaceuticals Announces Second Quarter 2022 Financial Results and Clinical Program Updates PR Newswire
Aug-03-22 10:00AM	Gain Therapeutics, Inc. (GANX) Expected to Beat Earnings Estimates: Should You Buy? Zacks
Aug-02-22 04:45PM	Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CNW Group
10:00AM	Will Fusion Pharmaceuticals Inc. (FUSN) Report Negative Q2 Earnings? What You Should Know Zacks
Jul-29-22 06:24AM	We're Keeping An Eye On Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate Simply Wall St.
Jul-07-22 07:55AM	Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
07:55AM	Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CNW Group
Jun-30-22 09:02AM	Top 10 Stock Picks of Jeffrey Diehls Adams Street Partners Insider Monkey
Jun-23-22 07:45AM	Fusion Pharmaceuticals Announces FDA Clearance of IND for FPI-2059, an Investigational Small Molecule-Based Radiopharmaceutical Targeting Solid Tumors Expressing NTSR1 PR Newswire -16.00%
07:45AM	Fusion Pharmaceuticals Announces FDA Clearance of IND for FPI-2059, an Investigational Small Molecule-Based Radiopharmaceutical Targeting Solid Tumors Expressing NTSR1 CNW Group
Jun-14-22 04:25PM	Fusion Pharmaceuticals Presents Imaging Data from Cold Antibody Sub-Study in the Phase 1 Study of FPI-1434 PR Newswire
04:25PM	Fusion Pharmaceuticals Presents Imaging Data from Cold Antibody Sub-Study in the Phase 1 Study of FPI-1434 CNW Group
Jun-10-22 07:42AM	Fusion Pharmaceuticals and Niowave Announce Actinium-225 Collaboration and Supply Agreement CNW Group
Jun-09-22 08:09AM	Fusion's stock falls 4% after announcing two clinical delays MarketWatch
07:00AM	Fusion Pharmaceuticals Provides Updates on FPI-1434 and FPI-1966 Clinical Programs PR Newswire
Jun-08-22 04:35PM	Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CNW Group
Jun-06-22 04:35PM	Fusion Pharmaceuticals to Present at the 2022 Jefferies Global Healthcare Conference PR Newswire
04:35PM	Fusion Pharmaceuticals to Present at the 2022 Jefferies Global Healthcare Conference CNW Group
May-20-22 11:08AM	How Many Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Shares Do Institutions Own? Simply Wall St.
May-11-22 04:45PM	Fusion Pharmaceuticals to Present at the Guggenheim Securities Radiopharmaceuticals Day PR Newswire -5.39%
04:45PM	Fusion Pharmaceuticals to Present at the Guggenheim Securities Radiopharmaceuticals Day CNW Group
May-10-22 07:00AM	Fusion Pharmaceuticals Announces First Quarter 2022 Financial Results and Clinical Program Updates PR Newswire
May-04-22 04:40PM	Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
04:40PM	Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CNW Group
Apr-26-22 04:40PM	Fusion Pharmaceuticals to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference PR Newswire -8.63%
Apr-20-22 10:33AM	Further weakness as Fusion Pharmaceuticals (NASDAQ:FUSN) drops 19% this week, taking one-year losses to 30% Simply Wall St.
Mar-30-22 04:35PM	Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
04:35PM	Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CNW Group
Mar-24-22 07:45AM	Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
07:45AM	Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CNW Group
Mar-17-22 07:00AM	Fusion Pharmaceuticals Announces Fourth Quarter 2021 Financial Results and Clinical Program Updates PR Newswire +11.38%
Mar-09-22 04:05PM	Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
04:05PM	Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CNW Group
Feb-28-22 04:15PM	Fusion Pharmaceuticals to Participate at the Cowen 42nd Annual Health Care Conference PR Newswire
04:15PM	Fusion Pharmaceuticals to Participate at the Cowen 42nd Annual Health Care Conference CNW Group
Feb-19-22 07:29AM	We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate Simply Wall St.
Feb-09-22 08:35AM	Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
08:35AM	Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CNW Group
Jan-21-22 08:30AM	Fusion Pharmaceuticals to Present at the B. Riley Securities 2022 Virtual Oncology Conference CNW Group
Jan-18-22 04:30PM	Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CNW Group
Jan-11-22 08:16AM	Fusion Pharmaceuticals Announces Research Collaboration with Pepscan to Develop Peptide-Based Radiopharmaceuticals PR Newswire +11.34%
08:16AM	Fusion Pharmaceuticals Announces Research Collaboration with Pepscan to Develop Peptide-Based Radiopharmaceuticals CNW Group
08:15AM	Fusion Pharmaceuticals Announces Research Collaboration with 48Hour Discovery to Develop Peptide-Based Radiopharmaceuticals PR Newswire
08:15AM	Fusion Pharmaceuticals Announces Research Collaboration with 48Hour Discovery to Develop Peptide-Based Radiopharmaceuticals CNW Group
Jan-10-22 04:30PM	Fusion Pharmaceuticals Announces Nomination of First Targeted Alpha Therapy Candidate in Collaboration with AstraZeneca to Advance into IND-Enabling Studies for Phase 1 Development PR Newswire
04:30PM	Fusion Pharmaceuticals Announces Nomination of First Targeted Alpha Therapy Candidate in Collaboration with AstraZeneca to Advance into IND-Enabling Studies for Phase 1 Development CNW Group
Dec-08-21 07:38PM	Tekla Healthcare Opportunities Fund Buys Moderna Inc, IDEXX Laboratories Inc, Sarepta ... GuruFocus.com
Nov-11-21 04:15PM	Fusion Pharmaceuticals To Present At The 2021 Jefferies London Healthcare Conference PR Newswire
04:15PM	Fusion Pharmaceuticals To Present At The 2021 Jefferies London Healthcare Conference CNW Group
Nov-09-21 07:30AM	Fusion Pharmaceuticals Announces Third Quarter 2021 Financial Results and Clinical Program Update CNW Group
Nov-03-21 04:30PM	Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CNW Group
Nov-02-21 04:15PM	Fusion Pharmaceuticals Appoints Industry Veteran Christopher Leamon, Ph.D., as Chief Scientific Officer PR Newswire
04:15PM	Fusion Pharmaceuticals Appoints Industry Veteran Christopher Leamon, Ph.D., as Chief Scientific Officer CNW Group
Oct-20-21 04:05PM	Fusion Pharmaceuticals Announces Presentation of Preclinical Data Supporting its FPI-1966 and FPI-2059 Targeted Alpha Therapies PR Newswire
04:05PM	Fusion Pharmaceuticals Announces Presentation of Preclinical Data Supporting its FPI-1966 and FPI-2059 Targeted Alpha Therapies CNW Group
Sep-28-21 04:05PM	Fusion Pharmaceuticals Appoints Mohit Rawat as President and Chief Business Officer PR Newswire
04:05PM	Fusion Pharmaceuticals Appoints Mohit Rawat as President and Chief Business Officer CNW Group
Sep-23-21 04:10PM	Fusion Pharmaceuticals To Present At The 2021 Cantor Fitzgerald Virtual Global Healthcare Conference PR Newswire
Sep-21-21 08:35AM	Fusion Pharmaceuticals Appoints Eric S. Hoffman, Ph.D. as Senior Vice President, Business Development PR Newswire
08:35AM	Fusion Pharmaceuticals Appoints Eric S. Hoffman, Ph.D. as Senior Vice President, Business Development CNW Group
Sep-02-21 04:10PM	Fusion Pharmaceuticals to Participate in Upcoming Investor Conferences PR Newswire
Aug-31-21 04:30PM	Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Aug-23-21 07:47AM	We Think Fusion Pharmaceuticals (NASDAQ:FUSN) Can Afford To Drive Business Growth Simply Wall St.
Aug-12-21 04:05PM	Fusion Pharmaceuticals and TRIUMF Announce Expanded R&D Collaboration for Actinium Supply Production PR Newswire
04:05PM	Fusion Pharmaceuticals and TRIUMF Announce Expanded R&D Collaboration for Actinium Supply Production CNW Group
Aug-10-21 07:30AM	Fusion Pharmaceuticals Announces Second Quarter 2021 Financial Results and Business Update PR Newswire
07:30AM	Fusion Pharmaceuticals Announces Second Quarter 2021 Financial Results and Business Update CNW Group
Aug-05-21 04:05PM	Fusion Pharmaceuticals to Participate in the 2021 Wedbush PacGrow Healthcare Virtual Conference PR Newswire
04:05PM	Fusion Pharmaceuticals to Participate in the 2021 Wedbush PacGrow Healthcare Virtual Conference CNW Group
Jul-28-21 04:15PM	Fusion Pharmaceuticals Announces FDA Clearance of IND for FPI-1966, an Investigational Radiopharmaceutical for the Treatment of Head and Neck and Bladder Cancers Expressing FGFR3 PR Newswire
04:15PM	Fusion Pharmaceuticals Announces FDA Clearance of IND for FPI-1966, an Investigational Radiopharmaceutical for the Treatment of Head and Neck and Bladder Cancers Expressing FGFR3 CNW Group
Jul-07-21 08:00AM	Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
08:00AM	Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CNW Group
Jun-14-21 04:10PM	Fusion Pharmaceuticals Announces Preliminary Safety and Dosimetry Results from its Single-Dose Portion of the Phase 1 Study of FPI-1434 PR Newswire
04:10PM	Fusion Pharmaceuticals Announces Preliminary Safety and Dosimetry Results from its Single-Dose Portion of the Phase 1 Study of FPI-1434 CNW Group
Jun-07-21 04:10PM	Fusion Pharmaceuticals Appoints Isabelle Dussault, Ph.D. as Senior Vice President, Research PR Newswire
04:10PM	Fusion Pharmaceuticals Appoints Isabelle Dussault, Ph.D. as Senior Vice President, Research CNW Group
Jun-02-21 08:30AM	Fusion Pharmaceuticals Enters into Agreement to Build Radiopharmaceutical Manufacturing Facility PR Newswire
08:30AM	Fusion Pharmaceuticals Enters into Agreement to Build Radiopharmaceutical Manufacturing Facility CNW Group
May-27-21 04:05PM	Fusion Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference CNW Group
May-25-21 03:08AM	What Kind Of Shareholders Hold The Majority In Fusion Pharmaceuticals Inc.'s (NASDAQ:FUSN) Shares? Simply Wall St.
May-11-21 07:30AM	Fusion Pharmaceuticals Announces First Quarter 2021 Financial Results and Business Update PR Newswire
07:30AM	Fusion Pharmaceuticals Announces First Quarter 2021 Financial Results and Business Update CNW Group
May-06-21 10:46AM	Fusion Pharma Shares Move Higher After Trial Collab With Merck For IGF-1R-Expressing Cancer Study Benzinga
08:20AM	Fusion Pharmaceuticals Announces Clinical Collaboration with Merck to Evaluate Fusion's Targeted Alpha Therapy (TAT) in Combination with Merck's KEYTRUDA® (pembrolizumab) in Patients With Solid Tumors Expressing IGF-1R PR Newswire
08:20AM	Fusion Pharmaceuticals Announces Clinical Collaboration with Merck to Evaluate Fusion's Targeted Alpha Therapy (TAT) in Combination with Merck's KEYTRUDA® (pembrolizumab) in Patients With Solid Tumors Expressing IGF-1R CNW Group
Apr-14-21 08:45AM	Fusion Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference PR Newswire
08:45AM	Fusion Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference CNW Group
Apr-10-21 08:35AM	Fusion Pharmaceuticals Announces Preclinical Combination Data Demonstrating Enhanced Efficacy in Multiple Preclinical Tumor Models CNW Group
Apr-01-21 04:15PM	Fusion Pharmaceuticals Announces Closing of Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen PR Newswire
04:15PM	Fusion Pharmaceuticals Announces Closing of Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen CNW Group
08:00AM	Fusion Pharmaceuticals Appoints Donald Bergstrom, M.D., Ph.D., to Board of Directors PR Newswire
08:00AM	Fusion Pharmaceuticals Appoints Donald Bergstrom, M.D., Ph.D., to Board of Directors CNW Group
Mar-26-21 03:51AM	Are Insiders Buying Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Stock? Simply Wall St. -5.95%
Mar-25-21 07:30AM	Fusion Pharmaceuticals Announces Fourth Quarter 2020 Financial Results and Business Update PR Newswire
07:30AM	Fusion Pharmaceuticals Announces Fourth Quarter 2020 Financial Results and Business Update CNW Group
Mar-02-21 07:30AM	Fusion Pharmaceuticals to Expand Pipeline with Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen PR Newswire

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company has a strategic collaboration agreement with AstraZeneca UK Limited to jointly discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GANNON STEVEN	Director	Aug 11	Buy	2.03	44,400	90,132	56,400	Aug 11 04:19 PM
Valliant John	Chief Executive Officer	Apr 27	Sale	6.03	4,511	27,201	318,147	Apr 27 04:34 PM
Valliant John	Chief Executive Officer	Apr 26	Sale	6.07	2,147	13,032	322,658	Apr 27 04:34 PM
Valliant John	Chief Executive Officer	Apr 25	Sale	6.03	2,036	12,277	324,805	Apr 27 04:34 PM
Valliant John	Chief Executive Officer	Apr 21	Sale	6.01	922	5,541	326,841	Apr 22 08:04 PM
Valliant John	Chief Executive Officer	Apr 20	Sale	6.02	367	2,209	327,763	Apr 22 08:04 PM
Valliant John	Chief Executive Officer	Apr 13	Sale	6.41	11,994	76,882	328,130	Apr 13 06:10 PM
Valliant John	Chief Executive Officer	Apr 12	Sale	7.10	18,255	129,610	340,124	Apr 13 06:10 PM
Valliant John	Chief Executive Officer	Apr 11	Sale	7.37	2,600	19,162	358,379	Apr 13 06:10 PM
Valliant John	Chief Executive Officer	Apr 08	Sale	7.52	826	6,212	360,979	Apr 08 04:21 PM
Valliant John	Chief Executive Officer	Apr 07	Sale	7.56	1,255	9,488	361,805	Apr 08 04:21 PM
Valliant John	Chief Executive Officer	Apr 06	Sale	7.58	100	758	363,060	Apr 08 04:21 PM
Valliant John	Chief Executive Officer	Apr 05	Sale	7.67	2,100	16,107	363,160	Apr 05 05:01 PM
Valliant John	Chief Executive Officer	Apr 04	Sale	7.81	700	5,467	365,260	Apr 05 05:01 PM
Valliant John	Chief Executive Officer	Apr 01	Sale	7.75	1,000	7,750	365,960	Apr 05 05:01 PM
Valliant John	Chief Executive Officer	Mar 30	Sale	7.52	300	2,256	366,960	Apr 01 05:36 PM
Valliant John	Chief Executive Officer	Mar 29	Sale	7.52	200	1,504	367,260	Mar 29 04:29 PM
Valliant John	Chief Executive Officer	Mar 28	Sale	7.55	9,600	72,480	367,460	Mar 29 04:29 PM
Valliant John	Chief Executive Officer	Mar 25	Sale	7.42	500	3,710	377,060	Mar 29 04:29 PM
Valliant John	Chief Executive Officer	Mar 23	Sale	7.50	100	750	378,260	Mar 24 05:32 PM
Valliant John	Chief Executive Officer	Mar 22	Sale	7.53	4,000	30,120	378,360	Mar 24 05:32 PM
Valliant John	Chief Executive Officer	Mar 21	Sale	7.46	700	5,222	377,560	Mar 24 05:32 PM
Valliant John	Chief Executive Officer	Mar 21	Sale	7.47	1,500	11,205	382,360	Mar 21 05:47 PM
Valliant John	Chief Executive Officer	Mar 18	Sale	7.61	1,204	9,162	383,860	Mar 21 05:47 PM
Valliant John	Chief Executive Officer	Mar 17	Sale	7.51	900	6,759	385,064	Mar 21 05:47 PM
Valliant John	Chief Executive Officer	Mar 16	Sale	6.99	100	699	385,964	Mar 16 04:29 PM
Valliant John	Chief Executive Officer	Mar 15	Sale	7.12	100	712	386,064	Mar 16 04:29 PM
Valliant John	Chief Executive Officer	Mar 14	Sale	6.96	1,300	9,048	386,164	Mar 16 04:29 PM
Valliant John	Chief Executive Officer	Mar 11	Sale	7.13	100	713	387,464	Mar 14 04:18 PM
Valliant John	Chief Executive Officer	Mar 10	Sale	7.06	1,900	13,414	387,564	Mar 14 04:18 PM
Valliant John	Chief Executive Officer	Mar 09	Sale	6.94	822	5,705	389,464	Mar 14 04:18 PM
Valliant John	Chief Executive Officer	Mar 08	Sale	6.92	3,004	20,788	390,286	Mar 08 04:59 PM
Valliant John	Chief Executive Officer	Mar 07	Sale	6.99	3,100	21,669	393,290	Mar 08 04:59 PM
Valliant John	Chief Executive Officer	Mar 04	Sale	7.32	8,400	61,488	396,390	Mar 08 04:59 PM
Valliant John	Chief Executive Officer	Mar 03	Sale	7.28	200	1,456	404,790	Mar 03 04:53 PM
Valliant John	Chief Executive Officer	Mar 02	Sale	7.44	26,546	197,502	404,990	Mar 03 04:53 PM
Valliant John	Chief Executive Officer	Mar 01	Sale	7.37	847	6,242	431,536	Mar 03 04:53 PM
Valliant John	Chief Executive Officer	Feb 28	Sale	7.40	3,100	22,940	432,383	Feb 28 07:13 PM
Valliant John	Chief Executive Officer	Feb 25	Sale	7.57	8,152	61,711	435,483	Feb 28 07:13 PM
Valliant John	Chief Executive Officer	Feb 24	Sale	7.41	2,500	18,525	443,635	Feb 28 07:13 PM
Valliant John	Chief Executive Officer	Feb 23	Sale	7.77	29,299	227,653	446,135	Feb 23 05:58 PM
Valliant John	Chief Executive Officer	Feb 22	Sale	7.85	4,100	32,185	475,434	Feb 23 05:58 PM
Valliant John	Chief Executive Officer	Feb 18	Sale	7.88	4,898	38,596	479,534	Feb 23 05:58 PM
Valliant John	Chief Executive Officer	Feb 17	Sale	7.98	1,700	13,566	484,432	Feb 17 05:39 PM
Valliant John	Chief Executive Officer	Feb 16	Sale	7.99	33,202	265,284	486,132	Feb 17 05:39 PM
Valliant John	Chief Executive Officer	Feb 15	Sale	8.33	12,600	104,958	519,334	Feb 17 05:39 PM
GANNON STEVEN	Director	Aug 23	Buy	7.99	2,829	22,590	12,000	Aug 23 06:28 PM
GANNON STEVEN	Director	Aug 19	Buy	8.05	3,000	24,150	9,171	Aug 20 04:10 PM
GANNON STEVEN	Director	Aug 18	Buy	8.05	171	1,377	6,171	Aug 20 04:10 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience